The PD-1-blocking antibody “nivolumab” is approved by the Food and Drug Administration for the treatment of metastatic melanoma, non-small cell lung cancer, classical Hodgkin’s lymphoma, and renal cell carcinoma [11]. Here, PDCD1 is linked to renal cell carcinoma.